Aldeyra Therapeutics Inc.

NASDAQ: ALDX · Real-Time Price · USD
5.37
0.07 (1.32%)
At close: Aug 15, 2025, 12:13 PM

Aldeyra Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
n/a n/a n/a n/a
Cost of Revenue
249.62K 262.78K 258.71K 264.18K
Gross Profit
-249.62K -262.78K -258.71K -264.18K
Operating Income
-60.12M -42.79M -62.68M -56.22M
Interest Income
6.19M 7.32M 2.35M 185.36K
Pretax Income
-55.85M -37.54M -62.02M -57.78M
Net Income
-55.85M -37.54M -62.02M -57.78M
Selling & General & Admin
11.89M 13.34M 15.37M 11.28M
Research & Development
48.23M 29.46M 47.31M 44.94M
Other Expenses
n/a n/a n/a n/a
Operating Expenses
60.12M 42.79M 62.68M 56.22M
Interest Expense
1.93M 2.07M 1.69M 1.74M
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
60.12M 42.79M 62.68M 56.22M
Income Tax Expense
n/a n/a n/a n/a
Shares Outstanding (Basic)
59.48M 58.94M 58.41M 54.04M
Shares Outstanding (Diluted)
59.48M 58.94M 58.41M 54.04M
EPS (Basic)
-0.94 -0.64 -1.06 -1.07
EPS (Diluted)
-0.94 -0.64 -1.06 -1.07
EBITDA
-53.68M -35.21M -60.07M -55.77M
EBIT
-53.93M -35.47M -60.33M -56.03M
Depreciation & Amortization
249.62K 262.78K 258.71K 264.18K